nach oben

Journal of Neurology

Erschienen in:

26.10.2019 | Original Communication

A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients

verfasst von: Federica Montagnese, Kristina Stahl, Stephan Wenninger, Benedikt Schoser

Erschienen in: Journal of Neurology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The symptomatic treatment of myotonia and myalgia in patients with dystrophic and non-dystrophic myotonias is often not satisfactory. Some patients anecdotally report symptoms’ relief through consumption of cannabis.

Methods

A combination of cannabidiol and tetrahydrocannabinol (CBD/THC) was prescribed as compassionate use to six patients (four patients with myotonic dystrophy types 1 and 2, and 2 patients with CLCN1-myotonia) with therapy-resistant myotonia and myalgia. CBD/THC oil was administered on a low dose in the first 2 weeks and adjusted to a higher dose in the following 2 weeks. Myotonia behaviour scale (MBS), hand-opening time, visual analogue scales (VAS) for myalgia and myotonia, and fatigue and daytime sleepiness severity scale (FSS, ESS) were performed weekly to monitor treatment response.

Results

All patients reported an improvement of myotonia especially in weeks 3 and 4 of treatment: MBS improved of at least 2 points in all patients, the hand-opening time variously improved in 5 out of 6 patients. Chronic myalgia was reported by both DM2 patients at baseline, one of them experienced a significant improvement of myalgia under treatment. Some gastrointestinal complaints, as abdominal pain and diarrhoea, improved in 3 patients; however, 4 out of 6 patients reported new-onset constipation. No other relevant side effect was noticed.

Conclusions

These first empirical results suggest a potentially beneficial role of CBD/THC in alleviating myotonia and should encourage further research in this field including a randomized-controlled trial on larger cohorts.

Wenninger S, Montagnese F, Schoser B (2018) Core clinical phenotypes in myotonic dystrophies. Front Neurol 9:303. https://doi.org/10.3389/fneur.2018.00303 CrossRefPubMedPubMedCentral

Miró J, Gertz KJ, Carter GT, Jensen MP (2014) Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain. Muscle Nerve 49(6):900–905. https://doi.org/10.1002/mus.24079.3 CrossRefPubMedPubMedCentral

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDer MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Mox-ley R (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79(4):348–357. https://doi.org/10.1212/WNL.0b013e318260cbe6 CrossRefPubMedPubMedCentral

Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT (2015) Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology 85(24):2136–2146. https://doi.org/10.1212/WNL.0000000000002225 CrossRefPubMedPubMedCentral

Johnson NE, Heatwole CR (2013) Teaching video neuroimages: trapezius myotonia percussion sign in myotonic dystrophy type 2. Neurology 80(24):e251. https://doi.org/10.1212/WNL.0b013e318296e905 CrossRefPubMedPubMedCentral

Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ (2012) Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 45(1):70–74. https://doi.org/10.1002/mus.22249 CrossRefPubMed

Sansone VA (2016) The dystrophic and nondystrophic myotonias. Continuum 22:1889–1915PubMed

Montagnese F, Schoser B (2018) Dystrophic and non-dystrophic myotonias. Fortschr Neurol Psychiatr 86(9):575–583. https://doi.org/10.1055/a-0635-8285 CrossRefPubMed

Cannon SC (2015) Channelopathies of skeletal muscle excitability. Compr Physiol 5(2):761–790. https://doi.org/10.1002/cphy.c140062 CrossRefPubMedPubMedCentral

10.

Trivedi JR, Cannon SC, Griggs RC (2014) Nondystrophic myotonia: challenges and future directions. Exp Neurol 253:28–30. https://doi.org/10.1016/j.expneurol.2013.12.005 CrossRefPubMed

11.

Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, Fontaine B, Amato AA, Barohn RJ, Griggs RC, Hanna MG, CINCH Investigators (2010) The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 133(Pt 1):9–22. https://doi.org/10.1093/brain/awp294 CrossRefPubMed

12.

Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG, Consortium for Clinical Investigation of Neurologic Channelopathies (2012) Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308(13):1357–1365. https://doi.org/10.1001/jama.2012.12607 CrossRefPubMedPubMedCentral

13.

Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, Stegeman DF, Timmermans J, Trivedi J, Matthews E, Saris CGJ, Schouwenberg BJ, Drost G, van Engelen BGM, van der Wilt GJ (2018) Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA 320(22):2344–2353. https://doi.org/10.1001/jama.2018.18020 CrossRefPubMedPubMedCentral

14.

Lorusso S, Kline D, Bartlett A, Freimer M, Agriesti J, Hawash AA, Rich MM, Kissel JT, David AW (2019) Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve 59(2):240–243. https://doi.org/10.1002/mus.26372 CrossRefPubMed

15.

Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J (2017) The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 140(9):2295–2305. https://doi.org/10.1093/brain/awx192 CrossRefPubMed

16.

Schneider-Gold C, Weber F, Schoser B, Ellrichmann G, Quasthoff S, Lehmann-Horn F, Sinnreich M (2018) Myotone Dystrophien, nicht dystrophe Myotonien und periodische Paralysen. Aktuelle Neurologie 45(03):167–177. https://doi.org/10.1055/s-0043-125352 CrossRef

17.

Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ, CINCH Consortium (2013) Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 136(Pt 7):2189–2200CrossRef

18.

Montagnese F, White M, Klein A, Stahl K, Wenninger S, Schoser B (2019) Cannabis use in myotonic dystrophy patients in Germany and USA: a pilot survey. J Neurol 266(2):530–532. https://doi.org/10.1007/s00415-018-9159-2 CrossRefPubMed

19.

Stockings E, Campbell G, Hall WD et al (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 159:1932–1954. https://doi.org/10.1097/j.pain.000000000000129329847469 CrossRefPubMed

20.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for medical use. JAMA 313:2456CrossRef

21.

Bagüés A, Martín MI, Sánchez-Robles EM (2014) Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Eur J Pharmacol 745:69–75. https://doi.org/10.1016/j.ejphar.2014.10.016 CrossRefPubMed

22.

Cavuoto P, McAinch AJ, Hatzinikolas G, Janovská A, Game P, Wittert GA (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364(1):105–110CrossRef

23.

Hammarén E, Kjellby-Wendt G, Lindberg C (2005) Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist. Neuromuscul Disord 15(9–10):610–617CrossRef

24.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP (2019) Medicinal use of cannabis based products and cannabinoids. BMJ 4(365):l1141. https://doi.org/10.1136/bmj.l1141 CrossRef

25.

Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20(Suppl 1):10–14. https://doi.org/10.1111/j.1365-2826.2008.01671.x CrossRefPubMed

26.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology 43(1):142–154. https://doi.org/10.1038/npp.2017.209 CrossRefPubMed

27.

Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277–296. https://doi.org/10.1016/j.tips.2015.02.008 CrossRefPubMedPubMedCentral

28.

Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153(2):199–215CrossRef

29.

Friedman D, French JA, Maccarrone M (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol 18(5):504–512. https://doi.org/10.1016/S1474-4422(19)30032-8 CrossRefPubMed

30.

Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol 10(4):443–455. https://doi.org/10.1080/17512433.2017.1292849 CrossRefPubMed

31.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041 CrossRefPubMed

32.

Fijał K, Filip M (2016) Clinical/therapeutic approaches for cannabinoid ligands in central and peripheral nervous system diseases: mini review. Clin Neuropharmacol 39(2):94–101CrossRef

33.

Oláh T, Bodnár D, Tóth A, Vincze J, Fodor J, Reischl B, Kovács A, Ruzsnavszky O, Dienes B, Szentesi P, Friedrich O, Csernoch L (2016) Cannabinoid signalling inhibits sarcoplasmic Ca2+ release and regulates excitation-contraction coupling in mammalian skeletal muscle. J Physiol 594(24):7381–7398CrossRef

34.

Iannotti FA, Pagano E, Moriello AS, Alvino FG, Sorrentino NC, D'Orsi L, Gazzerro E, Capasso R, De Leonibus E, De Petrocellis L, Di Marzo V (2019) Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol 176(10):1568–1584. https://doi.org/10.1111/bph.14460 CrossRefPubMed

35.

Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (2018) The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep 18(2):8. https://doi.org/10.1007/s11910-018-0814-x CrossRefPubMed

36.

Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S (2016) A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine 7:205–211. https://doi.org/10.1016/j.ebiom.2016.03.017Epub 2016 Mar 14 CrossRefPubMedPubMedCentral

37.

Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT, National Registry Scientific Advisory Committee/Investigators (2017) High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. Neurology 89(13):1348–1354. https://doi.org/10.1212/WNL.0000000000004420 CrossRefPubMedPubMedCentral

38.

Duncan M et al (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295:G78–G87CrossRef

39.

Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A crosssectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1(1):131–138. https://doi.org/10.1089/can.2016.0007 CrossRefPubMedPubMedCentral

Titel: A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients
verfasst von: Federica Montagnese
Kristina Stahl
Stephan Wenninger
Benedikt Schoser
Publikationsdatum: 26.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 2/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09593-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Machine-learning-derived rules set excludes risk of Parkinson’s disease in patients with olfactory or gustatory symptoms with high accuracy

Cardiorespiratory fitness as a quantitative predictor of the risk of stroke: a dose–response meta-analysis

Association between REM sleep behavior disorder and impulsive–compulsive behaviors in Parkinson’s disease: a systematic review and meta-analysis of observational studies

Pretreatment cerebral microbleeds and symptomatic intracerebral hemorrhage post-thrombolysis: a systematic review and meta-analysis

Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT